Trace Sensing Technologies

🌟 Trace Sensing: Wrapping Up 2024 with Momentum! 🌟 As we close out 2024, we’re reflecting on a year of incredible growth and innovation at Trace Sensing Technologies. Thanks to the support of our partners, investors, and the brilliant team behind our work, we’re ready to carry this momentum into an even brighter 2025. Here are some exciting highlights from Q4 that we’re especially proud of: 1️⃣ TRACE-E V2 – Development has kicked off on the next generation of TRACE-E. Faster, more accurate, and even more comfortable for patients—TRACE-E V2 is poised to revolutionize healthcare. 2️⃣ Boston PitchFest: Biotech Edition Finalist – Out of 72 top biotech innovators, we were honored to be selected as one of five finalists. It was amazing to connect with industry leaders and investors who share our vision! 3️⃣ New Funding Partnership – Big news: we’ve joined the SENTRY Center of Excellence! With a grant from DHS, we’re advancing our groundbreaking sensor technology to new heights. 4️⃣ KidneyX Sustainability Prize Submission – We’re proud to have submitted our application for the KidneyX Sustainability Prize! Our focus: developing affordable, early-stage screening for chronic kidney disease (CKD) to reduce the need for dialysis. By improving early detection, we can lower environmental impact—saving both lives and resources. A huge thank you to our entire community for your unwavering support. We couldn’t do this without you, and we’re excited about the opportunities ahead as we head into 2025! Wishing you all a joyful holiday season and a fantastic start to the new year! 🎉 #TraceSensing #Innovation #Biotech #Healthcare #Sustainability #2024Highlights #FutureofHealthcare

🚀 Big Things Happening at Trace Sensing – Q3 2024 🚀 It’s been a exciting quarter for the team – no time to rest when patients are waiting for innovative, life-changing solutions! Here’s a quick look at some key highlights as we continue pushing towards our vision of non-invasive, accurate diagnostic testing for all: 1️⃣ We’re proud to have delivered TRACE-E devices to Belgium to kick off the MAGEC Study(Molecular Analysis for Gastro-Esophageal Cancer) in partnership with Drs. Philippe Nafteux & Stijn Vanstraelen, MD Vanstraelen at UZ Leuven. 🇧🇪 2️⃣ What an inspiring day at the BioLabs Biotech Investor Day! It was incredible to connect with fellow health-tech innovators and showcase TRACE-E to an exceptional group of investors. 💡💬 3️⃣ Had the privilege of demoing TRACE-E for the 2024 Startup World Cup in the Rhode Island Regional Pitch Competition at Venture Café Providence. What a fantastic platform for networking and sharing our vision with the startup community! 🌱 4️⃣ We’ve ramped up our Seed funding round to accelerate growth and bring TRACE-E’s transformative diagnostic capabilities to more patients, faster. 📈💪 The response to TRACE-E has been nothing short of amazing, and we’re energized by the progress we’re making. Keep an eye on us as we continue to revolutionize healthcare one breath at a time. 💨 🔜 Q4 update coming soon – stay tuned and follow along for the latest! 👀 #HealthTech #Innovation #BreathAnalysis #Startups #MolecularDiagnostics #CKD #ENDAlz #Biotech

Last week we hosted our inaugural Boston PitchFest: Biotech Edition. Preparation for this event began eight months ago as Daniel Dacey and our Tech & VC Leader Bank team worked to curate incredible investors, companies, partners, exclusive offers for companies pitching, and a phenomenal venue space in Portal Innovations, LLC. With over 200 attendees and 50+ investors from angels, VCs, and innovation groups – we are proud to have made this our biggest event of the year. 72 companies pitched to 25 judges and 3 winners received Bio Partnering access at Bio 2025 (and additional investor dinners): Luca Giani of Ilios Therapeutics Avery (Qinghong) Yan, PhD, PhD of Riboway Therapeutics Brendan Walker of Chemeleon I want to give a shoutout to our partners who made this event possible: dovetail biopartners - Daniel Dacey. Also our co-host! Portal Innovations, LLC ➡️ Tatiana Yglesias Ulloa Dan Goddard Pliancy ➡️ John Masland Fidelity Private Shares – Kristen Craft Collaborative Drug Discovery - CDD Vault ➡️ Ralf Felsner & Jeremy Shelley Ontologic ➡️ Eli Pollock & Joyce Wang Hamilton, Brook, Smith & Reynolds, P.C.➡️ Chris Albert & Alexander Adam Egnyte ➡️ Abhay Kini & Bryant Donnowitz 🌟 Our volunteers who helped the event run smoothly and coordinated 72 companies pitching to two groups of judges (no small feat). Flora Hepp + Giselle Ventura + Arun Singh PhD + Sze-Wah 'Eva' Tse + Sepideh Ebadi Huge shout-out to Dave Hall for his excellent coaching at the pitch prep session! We are looking forward to planning more events like this next year. Reach out to myself or my Co-Director Alex Guinta if you want to learn more about how we work with startups at Leader Bank and what resources we can bring to the table.

🚨 UPDATE: Trace Sensing a Finalist at Boston PitchFest: Biotech Edition! We’re excited to announce that Trace Sensing Technologies was selected as a finalist at the inaugural Boston PitchFest: Biotech Edition! Out of 72 amazing companies, we were one of just five to pitch in the finals and engage with the judges. Huge thanks to the entire Trace Sensing team for their hard work! Beyond the competition, it was a fantastic opportunity to connect with leaders in the Boston biotech community. A special thank you to Daniel Dacey, Buzzed for Biotech, Vitaliy Schafer, Leader Bank, and all the sponsors for making this event a success. A big shoutout to Portal Innovations, LLC for hosting and providing the perfect backdrop for a great night of networking! We’re grateful for the continued support as we work toward a more effective, efficient, and affordable standard of care. Stay tuned for more updates!

Next Thursday, Trace Sensing is excited to share TRACE-E's innovative potential with more than 150 founders, investors and leaders from the Northeast biotech ecosystem at Boston PitchFest - Biotech Edition. Be sure to drop by and say hello to Peter Ricci III. Many thanks to event hosts and sponsors: Collaborative Drug Discovery - CDD Vault - Kristen Craft - Daniel Dacey - dovetail biopartners - Fidelity Investments - Alex Guinta - Hamilton, Brook, Smith & Reynolds, P.C. - Leader Bank - Pliancy - Portal Innovations, LLC and Vitaliy Schafer. See you there! https://lu.ma/trphyil9

🧠 Biogen's "Understanding Alzheimer's Disease" provides a thorough overview of how the brain changes due to Alzheimer's Disease. As the video notes, despite being asymptomatic, evidence shows that individuals with preclinical AD may exhibit biological changes in the brain indicative of AD pathogenesis 20 years prior to visible symptoms [1]. These biological changes include amyloid plaques, the misfolding, aggregation, and agglomeration of amyloid beta (Aβ) and tau tangles, the accumulation of folded tau proteins that have shifted from an unfolded coil to their “Alz50” configuration [2]. Early diagnosis, before the accumulation of plaques and the destruction of neural pathways is critical to patient outcomes. Understandably, diagnosing AD is complex. Current diagnostic techniques, immunoassays, MRI, PET, etc., lack the sensitivity and specificity to quantify the minute concentration changes that are expected to occur in the brain during preclinical AD. Trace Sensing is proud to contribute to this field of research as we expand our library of breath biomarkers. Having demonstrated TRACE-E's ability to detect biomarkers in breath for type 2 diabetes, breast cancer and others, we're taking our proven biomarker identification approach to Alzheimer’s Disease. Be sure to follow along for the latest news and study updates.

Paging Boston: TRACE-E is coming to a study near you! This week, Trace Sensing delivered TRACE-E devices as part of our collaboration with the Alzheimer’s experts at @BUMedicine --Rhoda Au, Katherine A. Gifford, PsyD, Kristi Ho, and Philip Joung. We look forward to the research we will do to deepen the understanding of Alzheimer’s pathology, validate Alzheimer’s biomarkers in breath and foster new hope for pre-clinical diagnostics of Alzheimer’s disease. Be sure to follow along for study updates.

🚨UPDATE: Trace Sensing Presented at Boston Biotech Investor Day 🚨 Trace Sensing introduced TRACE-E to the incredible audience at Boston Biotech Investor Day! It was a pleasure to share the Trace Sensing team's hard work on TRACE-E with the premier group of biotech investors in attendance. We were inspired to see many other health tech startups, such as MabLab, who share our desire to advance human health. Thank you to BioLabs, LabCentral, The Engine Accelerator for selecting us to participate in this great event! #LifeSciences #Biotech #Innovation #HumanHealth #startup

As the field of breathomics has grown, researchers have shown the potential it holds to improve disease diagnostics and patient outcomes. In Alzheimer's disease, studies have shown molecular changes in the brain can be detected up to 20 years before visible cognitive symptoms are observed. Building on this body of research has the potential to change the trajectory of the disease, leading to early detection, when interventions can be most effective. A 2019 pilot study by Tiele, et al found levels of acetone, 2-propanol and 2-butanone were statistically significant in distinguishing between participants with Alzheimer's, mild cognitive impairment and healthy participants. In addition, researchers have found connections between Alzheimer's disease and aldehydes, acetamide, and 1-phenanthrenol among other volatile organic compounds (VOCs). We will explore these and other VOCs in our upcoming study.

🚀 Revolutionizing Disease Diagnosis with TRACE-E: A Breakthrough in Breath Analysis 🫁 An accurate diagnosis is critical for patient outcomes. We believe TRACE-E will have a profound impact, providing non-invasive, real-time analysis of breath biomarkers linked to disease onset. Read on to learn more about TRACE-E and how it is differentiated from other diagnostic options. #InnovationInHealthcare #BreathBasedDiagnostics #DiseaseDiagnosis #Biomarkers #HealthcareInnovation #MedTech